Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, according to the agent’s manufacturer. Cemiplimab (Libtayo, Regeneron ...

“At the first prespecified interim analysis, Libtayo achieved a remarkably high bar in improving disease-free survival in high-risk cutaneous squamous cell carcinoma. With no currently approved ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

However, Regeneron recently announced that its PD-1 inhibitor LIBTAYO had met its primary endpoint among patients with high risk cutaneous squamous cell carcinoma (CSCC). This positive news in ...

Sanofi said the results are strong enough to support a new indication in the US and EU for Libtayo, a PD-1 inhibitor that is already FDA-approved in advanced cutaneous squamous cell carcinoma.

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

which evaluated the efficacy of the immunotherapy drug Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery. The trial met its primary ...

“At the first prespecified interim analysis, Libtayo achieved a remarkably high bar in improving disease-free survival in high-risk cutaneous squamous cell carcinoma. With no currently approved ...

which evaluated the efficacy of the immunotherapy drug Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery. The trial met its primary endpoint, ...